Doximity, DOCS Delivers a Cash-Willed Finish to Fiscal 2026 as AI Adoption Accelerates

Q4 2026 Highlights

• Revenue: $145.4 million in the fourth quarter, up 5% year over year from $138.3 million.
• Net income (GAAP): $19.1 million, or a net income margin of 13.1% (versus 45.2% in the prior-year period).
• Non-GAAP net income: $49.8 million, margin 34.2% (versus 56.2%).
• Adjusted EBITDA: $65.8 million, margin 45.3% (versus 50.4%).
• EPS: Diluted GAAP EPS of $0.10; non-GAAP diluted EPS of $0.26 (versus $0.31 and $0.38 in the year-ago quarter, respectively).
• Operating cash flow: $109.5 million; free cash flow of $107.3 million—each up about 11% year over year.

The company emphasized that the quarter’s results reflect ongoing momentum in its Clinical AI initiatives and a growing base of users. While the release doesn’t provide a formal revenue forecast, the Q4 results sit within a narrative of steady, cash-generative growth.

Note: The press release did not publish an explicit EPS consensus or a forward-looking revenue forecast, which leaves room for analyst interpretation on near-term earnings trajectory.

Fiscal Year 2026 Highlights

• Revenue: $644.9 million, up 13% year over year.
• Net income (GAAP): $196.1 million; margin 30.4% (versus 39.1% in the prior year).
• Non-GAAP net income: $302.7 million; margin 46.9% (versus 50.2%).
• Adjusted EBITDA: $357.8 million; margin 55.5% (versus 55.0%).
• EPS: Diluted GAAP EPS for the year not specified in a single line here, but the quarterly trend implies ongoing divergence between GAAP and non-GAAP measures; non-GAAP diluted EPS stood at $0.38 in the year-ago period, with 2026 figures reflecting continued discipline.
• Cash flow: Operating cash flow and free cash flow remained robust, reinforcing the company’s cash-generation profile.

Operational Momentum and AI Adoption

Management highlighted >800,000 active prescribers using its workflow tools in Q4, with nearly half engaging Clinical AI in the quarter. Notably, prompts per user nearly doubled from January to April, signaling a meaningful engagement lift as the AI suite embeds more deeply into in-workflow prescribing. This isn’t just a headline—it’s a pattern: a platform business that scales with its users’ dependence on AI-enabled features.

Partnerships announced during the period—with Aledade and Photon—aim to extend the Clinical AI Suite across thousands of independent practices and improve in-workflow prescribing for clinicians who want AI to stay in the loop rather than in a separate lab bench.

Leadership, Strategy, and a Subtle Rebalancing

The release notes leadership changes: Matt Sonefeldt is stepping in as Chief Financial Officer and Dr. Steve Zatz joins as President. The moves underscore a readiness to scale financial operations and executive leadership in support of expanding AI-driven products and the ongoing expansion of the user base.

What This Could Mean for Doximity and Its Peers

From a Matt Levine-flavored perspective, the story isn’t simply about top-line growth or one-off cash generation. Doximity’s 2026 results reveal a couple of meaningful trends: a growing EPS gap between GAAP and non-GAAP metrics that suggests ongoing adjustments in perception versus cash-friendly outcomes; and a much clearer signal that AI-adjacent features are moving from a “nice-to-have” to a “must-use” status for clinicians. The revenue forecast question remains unanswered in the release, but the 13% annual revenue lift hints at a durable demand tailwind, especially as AI capabilities reduce friction in routine prescribing workflows.

For sector peers, the Doximity story reinforces a broader theme: when AI becomes embedded in a professional network, the value creation isn’t only in new features but in unlocks of efficiency and user retention. The challenge will be sustaining >800,000 active prescribers in a competitive field, while maintaining EBITDA margins that can absorb continued AI investment.

Takeaways and What to Watch Next

• Debt-free or cash-rich model: Operating cash flow and free cash flow strength underpins ongoing reinvestment in AI, product development, and potential capital allocation actions.
• EPS and margin dynamics: GAAP EPS and net income margins softened year over year in Q4, even as non-GAAP metrics and EBITDA margins remained durable—watch how the company bridges GAAP and non-GAAP narratives in future quarters.
• AI adoption as a moat: The user base and AI engagement metrics suggest a network effect that could support long-run pricing power and higher per-user contribution margins if AI-driven workflows drive greater clinician productivity.
• Leadership pacing: The CFO and President additions point to an intent to scale operations and governance in step with growth in AI and international or new-partner initiatives.
• Peers’ response: If Doximity’s AI-driven workflow gains translate into stronger engagement and higher retention, other digital-health platforms may accelerate AI investments, potentially narrowing relative advantages in this space.

Bottom Line

DOCS’ 2026 results depict a company that has matured beyond pure user growth into a phase where AI-enabled workflows and a high-velocity prescriber network can translate into meaningful cash generation and margin resilience. The absence of a formal revenue forecast or an explicit EPS consensus in the release leaves a lot of questions for the street, but the cash flow machine is real, and the AI tailwinds appear substantive. For investors and peers, the central question is whether AI-enabled productivity translates into durable economics or simply accelerates near-term usage, a distinction that will unfold over the next several quarters.